Connect with us

Press Release

This Company Is Using AI To Establish Trust In A Digitally Connected World

Published

on

–News Direct–

By Faith Ashmore, Benzinga

In today's increasingly digital world, the prevalence of fraud is a growing concern. The rapid advancement of technology and the widespread use of the internet have created new opportunities for unscrupulous individuals to exploit unsuspecting individuals and organizations. With the convenience and anonymity offered by the digital space, scammers can carry out illegal activities from anywhere in the world with greater ease than ever before. From online identity theft to phishing scams, digital fraud has become more sophisticated, making it harder for people to detect and protect themselves. The sheer volume of personal and financial information being shared online also increases the risk of data breaches and unauthorized access.

Trust Stamp (NASDAQ: IDAI) is a company looking to revolutionize digital security and increase its penetration. The company is a global provider of AI-powered, privacy-first trust and identity services used across multiple sectors such as banking and finance, real estate, communications, regulatory compliance and government. Trust Stamp offers a range of innovative services. Their biometric capture and analysis technology enables secure and convenient identity verification, allowing businesses to streamline onboarding processes. By integrating advanced document verification, Trust Stamp helps verify the authenticity of important documents, reducing the risk of fraud.

In the face of increasing threats, Trust Stamp also provides cryptocurrency security and compliance solutions. Their expertise in this area assists businesses in safeguarding their digital assets, ensuring compliance with regulatory frameworks and protecting against unauthorized access or misuse. By facilitating accurate and reliable identity verification, Trust Stamp helps build trust between parties engaging in digital transactions, fostering secure interactions in a digital world.

Unlike other companies that may enable AI to make complex decisions regarding users' authentication and identification, Trust Stamp has constructed a process that uses ML and various metric and statistical methods to audit the AI system. Their AI is used to extract information needed for identity verification but does not make the final decision, which helps to ensure that all decisions made using their systems are transparent and auditable.

While Trust Stamps mission is similar to companies like Mitek (NASDAQ: MITK) and Nuance Communications (NASDAQ: NUAN), Trust Stamp has developed a proprietary process for tokenizing identity using an irreversible transformation via a convolutional neural network, creating an identity token known as IT2. The IT2 is generated by these AI processes, and data is removed and destroyed, making the token safe to store and reuse in the future. This process allows Trust Stamp to offer two unique value propositions to its customers: reauthentication and deduplication. Reauthentication enables users to reauthenticate using biometrics with ease, and deduplication allows for deduplication at scale to prevent synthetic identity fraud.

Additionally, Trust Stamp is utilizing AI to improve the capture process and enhance users' experience. Its work focuses on using AI and language models to dynamically instruct users on how to take a quality picture, guiding them on the necessary changes to phone position, lighting and head position, among other parameters. This technology not only makes facial matching accessible to those with special needs but also vastly reduces bias in outcomes from AI-powered decision processes.

As the digital landscape continues to evolve, Trust Stamp's emphasis on privacy and data protection is aimed at ensuring that users personal information is safeguarded at all times. By providing secure and trusted identity services, Trust Stamp positions itself as a crucial ally in the ongoing battle against fraud and identity-related issues, supporting a safer and more secure digital environment for all stakeholders.

This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice.

Contact Details

Benzinga

+1 877-440-9464

[email protected]

Company Website

http://www.benzinga.com

View source version on newsdirect.com: https://newsdirect.com/news/this-company-is-using-ai-to-establish-trust-in-a-digitally-connected-world-213593481

Benzinga

comtex tracking

COMTEX_441136188/2655/2023-09-28T09:15:20

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

The Beauty of Solid Wood Floors with Hardwood Flooring Group Inc.

Published

on

When it comes to flooring options, the modern homes have one of the very first things that comes to your mind that adds to beauty and elegance is the solid wood floors. That adds to the durability and elegance and enhances the aesthetic appeal of any given space.

At Hardwood Flooring Group, we invite you to check out the natural beauty and durability of wood flooring. Helping our customers to create spaces that are timeless and durable in nature as well. All those people who are looking to add to the benefits of using wood flooring should take a look at some of the reasons why we urge our customers to incorporate wood flooring for you and your loved ones in their homes and commercial settings.

Here is a brief insight into what solid wood flooring could do to your space.

The grace of solid wood flooring:

No matter if you are interested in creating a modern look for your home or still looking to delve into the traditional settings. We offer you to take a sneak peek into the solid wood flooring. And how it adds elegance and grace to any given space.

Solid woods exhibit warmth and richness to the flooring that no other flooring could promises to replicate. You could play around with the richness of the wood at the same time look forward to create a dignified play of color variation for any flooring.

For people who are looking to experiment with the color variation of the solid wood, you have the option to choose from walnut, solid red or white oak wood colors or the striking grain of the Hickory. At Hardwood Flooring Group, we promise to install sold wood flooring that matches any given theme, setting, or, most importantly, the style that you might want to portray in your wooden flooring.

Durability: 

While there are many other reasons why you should choose to go for the solid wood flooring and one among them is the ability to remain true to its nature for a very long time.

However, it is important to mention that the solid wood flooring requires proper maintenance and therefore, if maintained properly you could find them to be the perfect partner for your floors that lasts longer for generations to come.

The ability to stay in the same manner from season to season makes solid wood flooring one of the best choices for homemakers, builders and business owners because these floorings are not only appealing but also cost-effective.

Seamless integration:

When you take a look at solid wood flooring, we understand that different clients have different tastes in their flooring requirements, and therefore, the versatility in design and shape and, most importantly, the integrity of the flooring is what makes them so desirable. Moreover, the important aspect of solid wood flooring is the seamless integration that it offers to homeowners.

No matter what style you pick and what design that you prefer the solid wood flooring is what amalgamates to new and existing design seamlessly.

CONTACT DETAILS:

Website: https://www.woodfloorgroup.com/ 

Email: [email protected]

Phone Number: (954) 489-8384

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Expert Installation Services by Hardwood Flooring Group Inc.

Published

on

For all those who are seeking wood flooring solutions. We at Hardwood Flooring Group Inc. provide you with all the leading flooring solutions that are capable of seamlessly integrating into the existing theme and design of your space.

We are proud to provide flooring solutions that include installation, design and customization of Hardwood Flooring Group. Here, we are offering you solutions that are professional execution, ensuring that every flooring solution is built with precision and excellence.

However, if you are looking to get the new flooring installed, then look no further and choose Hardwood Flooring Group. Then there are some of the reasons why our clients choose us over others in the market.

Experience:

With tons of experience on the back, we are the ones who choose excellence and craftsmanship when it comes to the installation of hardwood flooring in your home. At Flooring Group Inc., we are a team of professional and dedicated craftsmen who are ready to provide you with exceptional services, immaculate finishes, and touches of elegance for your space.

Diversity:

While you take a look at some of the most diverse flooring options for your space, it is important to choose those that allow you to have versatility and diversity in your choice.

However, it is important to make sure that you prefer those who give you options in various techniques of installation. With hardwood, you always have a choice and the option of choosing flooring approaches that kick in right with your existing theme and design.

Detailed understanding:

With our expert consultation services, we are offering you a comprehensive understanding of your ideas and creative instinct and adding our expert experience to craft a final piece of flooring which matches no other. 

We at Hardwood Flooring Group INC. understands the fact that each of our client approaches our installation and consultation services with different ideas in mind. And we pay complete attention to the details and understands their perspective.

Precision installation:

Among many other reasons why you should choose our services over others, it is important to understand how our team works.

We are team of dedicated individuals who are ready to install, design and give you expert consultation services and that too under one roof. What separates us from others is our precision in installation.

We make sure that each plank is aligned and fitted and gives a finish that matches your expectations.

Commitment to time and cost:

We understand how excited our customers are to witness the final touches of Hardwood flooring, and therefore, we make no compromises to the time and cost of our installation services.

Our teams are dedicated to providing you with timely finishes, flawless touches, and prices that are sure not to match those of our service providers in the vicinity.

Hardwood Flooring Group Inc. is a hardwood flooring solution that sets no barrier when it comes to choosing quality, cost, and standard of material and installation services.

CONTACT DETAILS:

Website: https://www.woodfloorgroup.com/ 

Email: [email protected]

Phone Number: (954) 489-8384

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

China Medical System: Innovative Drug Methylthioninium Chloride Enteric-coated Sustained-release Tablets Approved for Marketing in China

Published

on

  • Innovative drug Methylthioninium Chloride Enteric-coated Sustained-release Tablets (Lumeblue®) is an oral diagnostic drug, approved by China’s NMPA for enhancing visualisation of colorectal lesions in adult patients undergoing screening or surveillance colonoscopy.
  • The results of the Phase III clinical trial in China show that the Product can significantly improve the detection rate of non-polypoid colorectal lesions (the primary endpoint of the study), leading to an improved detection rate of dangerous lesions such as non-polypoid adenomas (the secondary endpoint).
  • The Product can be taken during the bowel preparation step, ensuring that colorectal staining is completed by the time colonoscopy is conducted. This not only enhances the detection rate of colorectal lesions but also potentially simplifies the colonoscopy procedure, making the examination more efficient and improving the screening benefits.
  • As of now, CMS’s newly launched innovative portfolio has been expanded to 5 products, continuously generating driving force to the Group’s sustainable and healthy development.

 

SHENZHEN, CHINA – China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group” or CMS) is pleased to announce that on 11 June 2024, the New Drug Application (NDA) of the Group’s innovative drug methylthioninium chloride enteric-coated sustained-release tablets (Lumeblue®) (the “Product”) has been approved by the National Medical Products Administration of China (NMPA). The drug registration certificate was obtained on 18 June 2024. The Product is indicated to enhancing visualisation of colorectal lesions in adult patients undergoing screening or surveillance colonoscopy, and it is the first oral methylthioninium chloride enteric-coated sustained-release tablets in China. The Group will synergize with existing gastroenterology products and resources to advance the commercialization and academic promotion related works of the Product in an orderly manner, aiming to achieve nationwide large-scale clinical application as soon as possible so as to benefit patients with colorectal disease.

 

Lumeblue® is an oral diagnostic drug that uses patented multi-matrix (MMX) technology to deliver active substances directly to the colon and release them locally in a controlled manner. As an enhancer dye, the Product increases the contrast between colorectal lesions and healthy mucosa. The results of the Phase III clinical trial in China show that the Product can significantly improve the detection rate of non-polypoid colorectal lesions(the primary endpoint of the study), leading to an improved detection rate of dangerous lesions such as non-polypoid adenomas (the secondary endpoint)[1]. In addition, the Product can be taken during the bowel preparation step, ensuring that colorectal staining is completed by the time colonoscopy is conducted. This not only enhances the detection rate of colorectal lesions but also potentially simplifies the colonoscopy procedure, making the examination more efficient and improving the screening benefits.

 

According to the diagnosis and treatment data of the Digestive Endoscopy Branch of the Chinese Medical Association, approximately a total of 28 million gastroenteroscopies were completed nationwide in 2012, including 5.83 million colonoscopies. In 2019, approximately 38.73 million gastroenteroscopies were completed nationwide, an increase of 34.62% compared with 2012[2]. The Chinese consensus of early colorectal cancer screening recommends that people aged 50 to 75 years old should be screened for colorectal cancer regardless of whether they have alarm symptoms[3]. There are approximately 400 million people aged 50 to 75 in China in 2020[4]. With the popularity of early screening for colorectal cancer in China, it is expected to witness a considerable growth of the number of colonoscopies in China in the future.

 

The Product has been approved by the European Medicines Agency (EMA) to be commercialized in the European Union under the trade name Lumeblue™ in August 2020. The Group obtained an exclusive license for the Product from Cosmo Technologies Ltd, a fully owned subsidiary of Cosmo Pharmaceuticals NV, on 3 December 2020.

 

Driven by the twin-wheel of “Collaborative R&D and Independent R&D”, CMS has continuously deployed global first-in-class (FIC) and best-in-class (BIC) innovative products guided by patient and clinical demands. With enhancing R&D capabilities in developing differentiated innovative products, CMS has empowered the continuous transformation of scientific research outcomes into clinical application, continuously releasing the value of innovation. As of now, CMS’s newly launched innovative portfolio has been expanded to 5 products, continuously generating driving force to the Group’s sustainable and healthy development. Desidustat Tablets and Methotrexate Injection (rheumatoid arthritis), CMS’s innovative pipeline products, are currently under NDA review in China. Meanwhile, over 10 innovative pipeline products are undergoing clinical trials in China, mainly randomized controlled trials (RCT). CMS is expected to launch differentiated innovative products every year in the future with higher efficiency and more controllable costs, continuing to optimize its product portfolio and build fresh driving forces for the mid- to long-term development of the Company.

 

About CMS

CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.

 

CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.

 

CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries. While strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology business, CMS independently operates its dermatology and medical aesthetics business, and ophthalmology business, aiming to gain leading positions in specialty therapeutic fields, whilst enhancing the scale and efficiency. At the same time, CMS has expanded its business territory to the Southeast Asian market, striving to become a “bridgehead” for global pharmaceutical companies to enter the Southeast Asian market, further escorting the sustainable and healthy development of the Group.

 

Reference:

  1. The results of the Phase III clinical trial in China was published and can be found at: https://web.cms.net.cn/en/2022/12/positive-results-for-china-phase-iii-clinical-trial-of-methylthioninium-chloride-enteric-coated-sustained-release-tablets/
  2. The diagnosis and treatment data of the Digestive Endoscopy Branch of the Chinese Medical Association
  3. Chinese consensus of early colorectal cancer screening (2019, Shanghai)Chinese Journal of Internal MedicineDOI 10.3760/cma.j.issn.0578-1426.2019.10.004
  4. CHINA POPULATION CENSUS YEARBOOK 2020, can be found at https://www.stats.gov.cn/sj/pcsj/rkpc/7rp/zk/indexch.htm

 

CMS Disclaimer and Forward-Looking Statements

This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.

 

This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

 

Media Contact

Brand: China Medical System Holdings Ltd.

Contact: CMS Investor Relations

Email: [email protected]

Website: https://web.cms.net.cn/en/home/

Source: China Medical System Holdings Ltd.

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

LATEST POST